LV-HSC Platelet-Derived Factor VIII “Pleightlet™” for Severe Hemophilia A with Inhibitors
Time: 4:30 pm
day: Day One
Details:
- Summary of HSC gene therapy strategy for using platelet FVIII for hemophilia A
- Seminal pre-clinical and validation studies – in support of clinical efficacy
- Current status of the FDA approved phase I clinical trial
